Across TCGA pan-cancer cohorts, DAP3 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated DAP3 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher DAP3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DAP3 expression acts as an unfavorable survival marker.
KIRP are the cancer types where DAP3 Mutation most reproducibly stratifies survival.